Nkarta Inc

NKTXNASDAQ · USD
1.70USD0.00 (-7.11%)
215

Nkarta Inc (NKTX) Option Chain

As of October 27, 2026, Nkarta Inc is trading at $1.70, a -7.11% change from the previous close. The nearest expiration is Nov 20, 2026. Implied volatility is 186.4%. IV Rank is 85%.

Read more

Tracking the NKTX option chain helps you see every strike and expiry on Nkarta Inc in one view, so you can quickly identify the contracts that fit your thesis and your risk. Nkarta Inc's option chain lays out bids, asks, volume, open interest, and Greeks across calls and puts, giving you the full map of NKTX options activity at a glance. Use our scanner to monitor the NKTX option chain in real time and filter for the NKTX options trades that actually meet your criteria.

An option chain is the complete listing of all available option contracts on an underlying, organized by expiration date and strike price. For NKTX stock options, the chain shows side-by-side call and put data, making it easy to compare premiums, assess liquidity, and spot pricing dislocations. Reading the NKTX option chain effectively means looking beyond the last price — implied volatility by strike, volume-to-open-interest ratios, and bid-ask spreads all tell you where NKTX stock options are being actively traded and where they are not.

Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells.

The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Credit spreads, long calls, iron condors, calendar trades — every strategy starts with the same raw material: a clean, complete option chain. Our scanner pulls Nkarta Inc's full chain across every expiry, highlights the most liquid strikes, and lets you screen NKTX options by the metrics that matter, from IV skew to volume surges. Stop scrolling through endless rows of NKTX stock options — let the full option chain come to you, pre-filtered and ready to trade.

Stock Statistics

  • IndustryBiotechnology
  • SectorHealthcare
  • IV percentile91.27% Elevated
  • Market cap (M$)122
  • 52 weeks high-54.30%
  • 52 weeks low2.41%
  • Analyst recommendationStrong Buy
    1.00
  • Target price$10.83
    537.06% above the current stock price
  • Dividend—
  • Payout ratio—
  • Earnings date2026-11-10
  • P/E—
  • Future P/E—
  • EPS (ttm)-1.58
  • EPS growth next 5 years1.82%

As of October 27, 2026

2026-11-20
5 strikes
Default
CALLsPUTs
Prob. OTM %Open InterestVolumeExtrinsic ValueIntrinsic ValueBidAskStrikeMoneyness %BidAskIntrinsic ValueExtrinsic ValueVolumeOpen InterestProb. OTM %
80.512,06930.180.000.100.252.50+43.680.451.000.80-0.0809219.49
96.643,02800.100.00—0.105.00+187.362.803.703.30-0.0501023.36
99.1775200.750.00—0.757.50+331.035.306.305.800.00000.83

As of October 27, 2026

Scan the full option chain in one place

Browse the full NKTX option chain across every strike and expiration, filter by IV, volume, and open interest, and evaluate your trade without switching tools.

Start your 14-day free trial